CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Atropine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03544827
NCT03544827Phase 4Completed

The Effects of Low Dose Atropine on Choroidal Thickness

State University of New York College of Optometry·interventional·Posted Jun 4, 2018·Updated Feb 15, 2019

In Brief

A Phase 4 clinical trial evaluating Atropine for Myopia. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Atropine eye drops are considered to be an effective form of myopia control in human eyes. However, the mechanism by which it exerts it effects are not fully understood. Thickening of the choroid subsequent to atropine administration may play an important role in the mechanisms by which atropine induces myopia control. Literature also notes that choroidal thickness undergoes diurnal variations, which is a variable that will be controlled in this study in order to examine atropine's effects on different baseline choroidal thicknesses. The purpose of the proposed study is to characterize better the influence of atropine on choroid thickness. The study aims are to: 1. Determine the effect of low dose concentration of topical atropine (0.1% and 0.01%) on choroid thickness 2. Determine the effect of topical atropine on choroid thickness in relationship to baseline thickness throughout the day and after one week of daily instillation Hypothesis: Atropine's effect on choroidal thickness will be dependent on the subject's baseline thickness measurements, at a designated time of the day when the choroid is at its thinnest.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJun 4, 2018
Enrollment StartMay 21, 2018
Primary CompletionFeb 8, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.1 years ago

Interventions

Atropinedrug

Atropine 0.01% then atropine 0.1%

Atropinedrug

Atropine 0.1% then atropine 0.01%